Rocket One (RKTO) Change in Accured Expenses (2018 - 2026)
Rocket One's (RKTO) quarterly Change in Accured Expenses came in at -$48858.0 in Q2 2026, up 88.97% year-over-year from -$25854.3 in Q2 2025, and down 239.15% quarter-over-quarter from -$14406.0 in Q1 2026.
Analysis
Rocket One (RKTO) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Rocket One has disclosed Change in Accured Expenses across 6 years of filings, most recently posting -$48858.0 for Q2 2026.
- In Q2 2026, Change in Accured Expenses rose 88.97% year-over-year to -$48858.0; the TTM figure through Jun 2026 stood at $1.0 million (up 438.4% YoY), while the FY2025 annual figure was $644166.0, up 320.99% from the prior year.
- Change in Accured Expenses came in at -$48858.0 for Q2 2026 at Rocket One, down from -$14406.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $655781.0 in Q3 2025 to a low of -$1.2 million in Q4 2023.
- Average Change in Accured Expenses over 4 years is -$24814.2, with a median of $4599.5 recorded in 2024.
- The largest YoY upside for Change in Accured Expenses was 1797.53% in 2025 against a maximum downside of 1201.14% in 2025.
- Over 4 years, Change in Accured Expenses stood at -$1.2 million in 2023, then jumped by 101.91% to $23605.0 in 2024, then jumped by 1797.53% to $447912.0 in 2025, then plunged by 110.91% to -$48858.0 in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$48858.0 in Q2 2026, -$14406.0 in Q1 2026, and $447912.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -13.91 Mn |
| 10 | Rocket One | 13.86 Mn | 5.97 Mn | - | -48,858.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -48,858.00 |
| Mar 31, 2026 | -14,406.00 |
| Dec 31, 2025 | 447,912.00 |
| Sep 30, 2025 | 655,781.00 |
| Jun 30, 2025 | -443,132.00 |
| Mar 31, 2025 | -16,395.00 |
| Dec 31, 2024 | 23,605.00 |
| Sep 30, 2024 | 128,470.00 |
| Jun 30, 2024 | 40,243.00 |
| Mar 31, 2024 | -39,305.00 |
| Dec 31, 2023 | -1.24 Mn |
| Sep 30, 2023 | 207,182.00 |
| Jun 30, 2019 | 9,795.00 |
| Mar 31, 2019 | 17,332.00 |
| Dec 31, 2018 | 208,213.00 |